Bayesian nonparametric estimation of ROC surface under verification bias.
Bayes Theorem
Bias
Biomarkers, Tumor
/ blood
Biostatistics
CA-125 Antigen
/ blood
Carcinoma, Hepatocellular
/ blood
Carcinoma, Ovarian Epithelial
/ blood
Computer Simulation
Diagnostic Tests, Routine
/ statistics & numerical data
Female
Humans
Liver Neoplasms
/ blood
Male
Membrane Proteins
/ blood
Models, Statistical
Ovarian Neoplasms
/ blood
Prognosis
ROC Curve
Serum Albumin, Human
Statistics, Nonparametric
WAP Four-Disulfide Core Domain Protein 2
/ metabolism
Bayesian bootstrap
Dirichlet process
MAR assumption
ROC surface
verification bias correction
Journal
Statistics in medicine
ISSN: 1097-0258
Titre abrégé: Stat Med
Pays: England
ID NLM: 8215016
Informations de publication
Date de publication:
15 08 2019
15 08 2019
Historique:
received:
18
09
2018
revised:
19
02
2019
accepted:
06
04
2019
pubmed:
3
5
2019
medline:
21
10
2020
entrez:
4
5
2019
Statut:
ppublish
Résumé
The receiver operating characteristic (ROC) surface, as a generalization of the ROC curve, has been widely used to assess the accuracy of a diagnostic test for three categories. A common problem is verification bias, referring to the situation where not all subjects have their true classes verified. In this paper, we consider the problem of estimating the ROC surface under verification bias. We adopt a Bayesian nonparametric approach by directly modeling the underlying distributions of the three categories by Dirichlet process mixture priors. We propose a robust computing algorithm by only imposing a missing at random assumption for the verification process but no assumption on the distributions. The method can also accommodate covariates information in estimating the ROC surface, which can lead to a more comprehensive understanding of the diagnostic accuracy. It can be adapted and hugely simplified in the case where there is no verification bias, and very fast computation is possible through the Bayesian bootstrap process. The proposed method is compared with other commonly used methods by extensive simulations. We find that the proposed method generally outperforms other approaches. Applying the method to two real datasets, the key findings are as follows: (1) human epididymis protein 4 has a slightly better diagnosis ability compared to CA125 in discriminating healthy, early stage, and late stage patients of epithelial ovarian cancer. (2) Serum albumin has a prognostic ability in distinguishing different stages of hepatocellular carcinoma.
Substances chimiques
Biomarkers, Tumor
0
CA-125 Antigen
0
MUC16 protein, human
0
Membrane Proteins
0
WAP Four-Disulfide Core Domain Protein 2
0
WFDC2 protein, human
0
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3361-3377Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 John Wiley & Sons, Ltd.